<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04961710</url>
  </required_header>
  <id_info>
    <org_study_id>HR-TPO-SAA-III-EXT</org_study_id>
    <nct_id>NCT04961710</nct_id>
  </id_info>
  <brief_title>Extension Study of Hetrombopag in Severe Aplastic Anemia</brief_title>
  <official_title>Extension Study of Hetrombopag Olamine in Patients With Treatment-naive Severe Aplastic Anemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, placebo-control, phase 3 study of hetrombopag in patients with&#xD;
      treatment-naive severe aplastic anemia. All subjects who have completed or withdrawn from the&#xD;
      HR-TPO-SAA-III study will voluntarily participate in this extension study.&#xD;
&#xD;
      Subjects will receive the same study drug (hetrombopag or placebo) as in study&#xD;
      HR-TPO-SAA-III, with the same doses and administration schedule or with modifications based&#xD;
      on the actual conditions.&#xD;
&#xD;
      The primary objective of this extension study is to give the subjects participating in the&#xD;
      HR-TPO-SAA-III study the continued access to the study drug (hetrombopag or placebo) after&#xD;
      the completion of the HR-TPO-SAA-III study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 19, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The ratio of subjects with clonal evolution at 6 months and 18 months</measure>
    <time_frame>6 months and 18 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>All SIEs, regardless of whether they are related to the investigational product</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>All SAEs, regardless of whether they are related to the investigational product</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>All AEs resulting in discontinuation and withdrawal from study</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Red blood cell count</measure>
    <time_frame>by 1day visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin</measure>
    <time_frame>by 1day visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet count</measure>
    <time_frame>by 1day visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>White blood cell count</measure>
    <time_frame>by 1day visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neutrophil count</measure>
    <time_frame>by 1day visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reticulocyte count</measure>
    <time_frame>by 1day visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The 6-month and 18-month survival rates of subjects</measure>
    <time_frame>6 months and 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The recurrence rates at 6 months and 18 months</measure>
    <time_frame>6 months and 18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Treatment-naive Severe Aplastic Anemia</condition>
  <arm_group>
    <arm_group_label>Hetrombopag Olamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hetrombopag Olamine</intervention_name>
    <description>Hetrombopag Olamine; once daily</description>
    <arm_group_label>Hetrombopag Olamine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo; once daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects who have completed or withdrawn from the HR-TPO-SAA-III study&#xD;
&#xD;
          2. Subjects who have signed the informed consent form&#xD;
&#xD;
          3. Female and male subjects of childbearing age who agree to take adequate contraceptive&#xD;
             measures during the extension study period and within 28 days after the last dose&#xD;
&#xD;
          4. Subjects who have completed the end-of-treatment evaluation in the original study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any unstable situation or situation that will compromise the safety of the subject&#xD;
&#xD;
          2. Evidence of clonal cytogenetic abnormalities at the end-of-treatment examination of&#xD;
             the HR-TPO-SAA-III study&#xD;
&#xD;
          3. Subjects with uncontrollable hemorrhage and/or infection after standard treatment&#xD;
&#xD;
          4. Subjects who have experienced deep vein thrombosis, myocardial infarction, stroke, or&#xD;
             peripheral arterial embolism within 1 year&#xD;
&#xD;
          5. Any situation that may compromise the subject and the safety or compliance thereof&#xD;
             during the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yaqi Shen</last_name>
    <phone>021-61053363</phone>
    <email>yaqi.shen@hengrui.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Blood Diseases Hospital, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Fengkui Zhang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 12, 2021</study_first_submitted>
  <study_first_submitted_qc>July 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 14, 2021</study_first_posted>
  <last_update_submitted>July 13, 2021</last_update_submitted>
  <last_update_submitted_qc>July 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

